Growth Metrics

Gilead Sciences (GILD) Shareholder's Equity Growth (1y) (2010 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 23.26%
Dec 31, 2025 17.96%
Sep 30, 2025 17.13%
Jun 30, 2025 7.66%
Mar 31, 2025 9.30%
Dec 31, 2024 -15.40%
Sep 30, 2024 -17.32%
Jun 30, 2024 -13.73%
Mar 31, 2024 -16.64%
Dec 31, 2023 7.26%
Sep 30, 2023 5.63%
Jun 30, 2023 4.35%
Mar 31, 2023 5.14%
Dec 31, 2022 0.69%
Sep 30, 2022 -1.93%
Jun 30, 2022 2.56%
Mar 31, 2022 5.01%
Dec 31, 2021 15.60%
Sep 30, 2021 22.90%
Jun 30, 2021 8.64%
Mar 31, 2021 -14.50%
Dec 31, 2020 -19.55%
Sep 30, 2020 -15.75%
Jun 30, 2020 -20.26%
Mar 31, 2020 0.40%
Dec 31, 2019 5.18%
Sep 30, 2019 -9.87%
Jun 30, 2019 4.68%
Mar 31, 2019 6.97%
Dec 31, 2018 5.04%
Sep 30, 2018 -7.40%
Jun 30, 2018 -5.88%
Mar 31, 2018 1.03%
Dec 31, 2017 5.88%
Sep 30, 2017 47.29%
Jun 30, 2017 43.29%
Mar 31, 2017 45.81%
Dec 31, 2016 1.31%
Sep 30, 2016 -3.14%
Jun 30, 2016 -3.12%
Mar 31, 2016 -18.40%
Dec 31, 2015 20.82%
Sep 30, 2015 25.61%
Jun 30, 2015 1.25%
Mar 31, 2015 28.33%
Dec 31, 2014 34.69%
Sep 30, 2014 27.38%
Jun 30, 2014 48.12%
Mar 31, 2014 28.82%
Dec 31, 2013 23.06%
Sep 30, 2013 26.50%
Jun 30, 2013 38.61%
Mar 31, 2013 42.10%
Dec 31, 2012 38.98%
Sep 30, 2012 38.03%
Jun 30, 2012 32.34%
Mar 31, 2012 18.43%
Dec 31, 2011 12.17%
Sep 30, 2011 9.23%
Mar 31, 2011 -17.69%
Dec 31, 2010 -5.89%
Sep 30, 2010 1.06%